BLUE250117C4500
- 0.05
- 0.000.00%
bluebird bio Newsroom
Express News | Bluebird bio Inc : Leerink Partners Raises Target Price to $10 From $1
Bluebird Bio Is Maintained at Overweight by Barclays
Bluebird Bio Analyst Ratings
Barclays Maintains Bluebird Bio(BLUE.US) With Buy Rating, Maintains Target Price $40
Bluebird Bio, Inc. (BLUE): Is This Gene Therapy Stock a Good Buy Right Now?
Investor Optimism Abounds Bluebird Bio, Inc. (NASDAQ:BLUE) But Growth Is Lacking
Bluebird Bio Trading Halted, News Pending
Express News | Trading Halt: Halted at 7:50:00 P.m. ET - Trading Halt: Halt News Pending
Bluebird Bio To Carry Out 1-for-20 Reverse Stock Split On December 13th, 2024
Reported Sunday, Bluebird Bio Highlights 9-Year Data For LYFGENIA Gene Therapy: Sustained Benefits In Sickle Cell Disease Patients At ASH 2024
Bluebird Bio Announced Long-Term Follow-Up Data Continue To Support Beti-Cel As Potentially Curative Gene Therapy For Β-Thalassemia Patients Who Require Regular Transfusions Through Achievement Of Durable Transfusion Independence And Normal Or...
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Trending Stocks Today | PainReform Surges 67.16% Post-Market
Express News | Bluebird bio Announces 1-for-20 Reverse Stock Split
Bluebird Bio Announces 1-for-20 Reverse Stock Split
FDA-Approved Sickle Cell Therapies From Bluebird Bio And Vertex Join Medicaid Innovation Program
Bluebird Bio Shares Are Trading Higher After the Company Announced It Joined the CMMI Cell and Gene Therapy Access Model and Will Offer Outcomes-based Agreements to Expand Medicaid Access to LYFGENIA Gene Therapy for Sickle Cell Disease.
CMS Rolls Out New Payment Model for Vertex, Bluebird Gene Therapies
Bluebird Bio Participates in CMMI Cell and Gene Therapy Access Model
Express News | CMS: Cell & Gene Therapy Access Model Launches in Jan 2025, States May Choose to Begin Participation Anytime Between Jan 2025 & Jan 2026